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Abstract
Background: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a loss of dopaminergic
neurons (DN) in the substantia nigra (SN). Several lines of evidence suggest that apoptotic cell death of DN is
driven in part by non-cell autonomous mechanisms orchestrated by microglial cell-mediated inflammatory
processes. Although the mechanisms and molecular network underlying this deleterious cross-talk between DN and
microglial cells remain largely unknown, previous work indicates that, upon DN injury, activation of the β2 integrin
subunit CD11b is required for microglia-mediated DN cell death. Interestingly, during brain development, the
CD11b integrin is also involved in microglial induction of neuronal apoptosis and has been shown to act in concert
with the DAP12 immunoreceptor. Whether such a developmental CD11b/DAP12 pathway could be reactivated in a
pathological context such as PD and play a role in microglia-induced DN cell death is a tantalizing hypothesis that
we wished to test in this study.
Methods: To test the possibility that DAP12 could be involved in microglia-associated DN injury, we used both
in vitro and in vivo toxin-based experimental models of PD recapitulating microglial-mediated non-cell autonomous
mechanisms of DN cell death. In vitro, enriched mesencephalic neuronal/microglial co-cultures were exposed to the
dopaminergic neurotoxin 1-methyl-4-phenylpyridinium (MPP+) whereas in vivo, mice were administrated with 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) according to acute or subchronic mode. Mice deficient for
DAP12 or CD11b were used to determine the pathological function of the CD11b/DAP12 pathway in our disease
models.
Results: Our results show that DAP12 and CD11b partially contribute to microglia-induced DN cell death in vitro.
Yet, in vivo, mice deficient for either of these factors develop similar neuropathological alterations as their wild-type
counterparts in two different MPTP mouse models of PD.
Conclusion: Overall, our data suggest that DAP12 and CD11b contribute to microglial-induced DN cell death
in vitro but not in vivo in the MPTP mouse model of PD. Therefore, the CD11b/DAP12 pathway may not be
considered as a promising therapeutic target for PD.
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Background
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by a loss of dopaminergic neurons (DN) in
the substantia nigra (SN). Although the mechanism by
which these neurons degenerate is still uncertain, several
lines of evidence suggest that apoptotic cell death of DN
is driven in part by non-cell autonomous mechanisms
implicating microglial cells and inflammatory processes
[1]. Current hypothesis suggests that DN injury initiated
by as-yet to be identified etiological factors triggers
microglial cell activation, which in turn set off harmful
inflammatory mechanisms involved in a vicious cycle of
neuronal cell death. Among the different scenarios under-
lying microglial neurotoxicity during PD-like nigrostriatal
pathway injury, the production of toxic levels of reactive
oxygen (ROS) and nitrogen species by activated microglial
cells is believed to be a major threat for DN survival [1].
This view is supported by experimental findings showing
that genetic ablation of some of the key enzymatic systems
involved in macrophage-associated respiratory burst (indu-
cible nitric oxide synthase and nicotinamide adenine di-
nucleotide phosphate-oxidase (NADPH)-oxidase) provides
neuroprotection in animal models of PD [2,3].
The molecular signals from the dying/suffering DN
neurons that trigger microglial cell activation and the
oxidative burst are still largely unknown. Yet, recent evi-
dence indicate that microglial CD11b, the alpha M sub-
unit of the MAC1 β2 integrin, is likely to be involved in
NADPH-oxidase activation and superoxide production
[4,5]. This process is reminiscent to the mechanisms
used by peripheral macrophages and neutrophils to trig-
ger the death of invading pathogens through CD11a- or
CD11b-mediated ROS production [6,7]. In this context,
β2 integrin signaling has been shown to proceed by an
immunoreceptor-like mechanism that involves adaptors
containing immunoreceptor tyrosine-based activation
motifs (ITAMs) including DAP12 and FcRγ [8]. With re-
spect to the CNS, a CD11b/DAP12 pathway has been
previously implicated in the induction of developmental
neuronal apoptosis by microglial cells in the hippocam-
pus [9]. Although still debated, DAP12 expression is
usually undetected or poorly detected in the adult brain
and has been shown to be restricted to developing
microglia [10,11]. Whether such developmental pathway
of neuronal cell death could be reactivated in adulthood
under specific neuropathological circumstances such as
PD is an open question.
To test this hypothesis, we used both in vitro and in vivo
models of PD recapitulating microglia-mediated non-cell
autonomous mechanisms of DN neurodegeneration. We
found that whereas DAP12 and CD11b partially contribute
to microglia-induced DN cell death in vitro, mice deficient
for either of these factors develop similar neuropatho-
logical alterations to their wild-type (WT) counterparts in
two different 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) mouse models of PD.
Methods
Animals
C57BL/6J mice (Janvier Breeding Center, Le Genest St Isle,
France), DAP12-mutated mice (DAP12KI) on C57BL/6 gen-
etic background [12] and CD11b-deficient mice (B6.129S4-
Itgamtm1Myd/J on C57BL/6 background obtained from the
Jackson Laboratory) were used. For in vitro experiments,
primary mesencephalic neurons were prepared from gesta-
tional age 13 days C57BL/6J mice embryos whereas pri-
mary microglial cells were obtained from newborn C57BL/
6J, DAP12KI or CD11b−/− mice. For in vivo experiments,
ten- to twelve week-old male C57BL/6J, DAP12KI and
CD11b−/− mice, weighing 25 to 30 g were used. Mice were
kept in a temperature-controlled room (23°C ± 1°C)
under a 12-hour light/dark cycle and had ad libitum ac-
cess to food and water. All animals were further geno-
typed after their sacrifice. Animal handling was carried
out according to ethical regulations and guidelines
(Guide for the care and use of laboratory animals, NIH
publication no. 85–23, revised 1985) and the European
Communities Council Directive 86/609/EEC. Experi-





hydrochloride (MPTP-HCl) were purchased from Sigma-
Aldrich (St Quentin-Fallavier, France). Dihydrorhodamine-
123 (DHR-123), the cell permeant probes used for the
detection of ROS was purchased from Molecular Probes
(Invitrogen, CergyPontoise, France).
Midbrain cell cultures
Cultures were prepared from the ventral mesencephalon
of gestational age 13 days C57BL/6J mice embryos.
Dissociated cells in suspension obtained by mechanical
trituration of midbrain tissue pieces were seeded at a
density of 1.2 to 1.5 × 105 cells/cm2 onto tissue culture
supports pre-coated with 1 mg/mL polyethylenimine
(Sigma-Aldrich, St Quentin-Fallavier, France). The cul-
tures were then maintained in N5 medium supplemented
with 5 mM glucose, 5% horse serum, and 0.5% fetal calf
serum, except for the first 3 days in vitro (DIV) during
which the concentration of fetal calf serum was set at
2.5% to favor initial maturation of the cultures [13]. Note
that tyrosine hydroxylase-positive (TH+) neurons repre-
sent approximately 1 to 2% of the total number of neur-
onal cells present in these cultures.
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Highly enriched microglial cell cultures
Microglial cells were derived from the cerebral cortex of
newborn C57BL/6J, DAP12KI or CD11b−/− mice,
according to procedures described previously [14]. Pure
ameboid microglial cells (>99%) were isolated from
2-week-old primary glial cultures grown in DMEM
supplemented with 10% fetal calf serum. The cells were
washed three times in DMEM and plated in CDM (1 to
1.5 × 106 cells per 35 mm dish).
Mixed neuron/microglia cultures
Freshly isolated microglial cells (1 to 2.105 cells/well)
were added to 4-DIV primary neuronal cultures grown
in 24-well plates. Control neuronal cultures were sup-
plemented with an equal volume of cell-free medium.
LPS (serotype 026:B6, Escherichia coli, at 100 ng/mL) or
MPP+, at 0.1 μM, were applied directly to the mixed cul-
tures at 5-DIV, that is, one day after the seeding of
microglial cells on primary neurons.
Immunofluorescent detection protocols
The cultures were fixed for 12 minutes using 4% formal-
dehyde in Dulbecco’s (PBS), and then washed twice with
PBS before an incubation step at 4°C for 24 to 72 h with
the following antibodies. A monoclonal anti-TH anti-
body diluted 1/5000 (Diasorin, Stillwater, MN, USA) was
used to assess the survival of DN. Microglial cells were
characterized using a mouse anti-CD11b antibody (1/50;
clone MRC OX-42; Serotec, Oxford, England). All anti-
bodies were diluted in PBS containing 0.2% Triton X-
100 except the mouse anti-CD11b antibody, which was
diluted in PBS only. Detection of the primary antibodies
was performed with a cyanin-3 conjugate of an anti-
mouse IgG antibody (1/500, Sigma Aldrich) or with an
Alexa Fluor 488 conjugate of an anti-rabbit antibody (1/
500; Invitrogen, Carlsbad, CA, USA). Cell counting was
performed at 200× magnification using a 20× objective
matched with a 10× ocular. The number of TH+ neu-
rons in each culture well was estimated after counting
20 visual fields distributed along the X and Y axes. Note
that counts of neuronal cells were performed at 13-DIV,
that is, at a stage when the death process affecting DA
neurons is almost fully complete.
Quantification of superoxide ions
Superoxyde ion (O2
.-) levels were measured using dihydr-
oethidium (Invitrogen) as fluorescent probes at 6-DIV,
that is, when oxidative stress is at its peak. Mixed
microglia-neuron cultures were exposed for 30 minutes
to 1 μM dihydroethidium, washed three times, and then
maintained in serum-free supplemented medium. The
fluorescent signal, visualized by epifluorescence micros-
copy (excitation at 520 nm, emission at 610 nm), was
quantified using the Simple-PCI software from C-
Imaging Systems (Cranberry Township, PA, USA) and a
Nikon TE-300 inverted microscope equipped with an
ORCA-ER digital camera (Hamamatsu Photonics, Massy,
France). Fluorescent images of randomly chosen fields (six
to eight in each culture condition) were acquired with a
20× fluorescent objective. The average pixel intensity over
the surface of each cell body was determined under the
different test conditions. Background fluorescence was
subtracted from raw data, and the results were expressed
as a percentage of the mean fluorescence intensity per cell
in control cultures. A minimum of 60 cells was analyzed
under each test condition.
MPTP injection and tissue preparation
Groups of mice received MPTP under a subchronic or
acute protocol. For subchronic MPTP intoxication, mice
were given an intra-peritoneal (i.p.) injection of 30 mg/kg
(free base) MPTP-HCl per day for 5 consecutive days and
were then euthanized at 1, 2, 4, 7 or 21 days after the last
MPTP injection. For acute MPTP intoxication, mice were
i.p.-injected with 4 doses of 20 mg/kg (free base) MPTP-
HCl at 2-h intervals and were then euthanized 2 or 7 days
after the last MPTP injection. Control mice received an
equivalent volume of 0.9% NaCl solution. For immunohis-
tochemistry, mice were injected with a lethal dose of
pentobarbital (100 mg/kg) and then transcardially per-
fused with 50 mL of heparin solution (5 U/mL) followed
by 100 mL of ice-cold 4% paraformaldehyde (PFA) solu-
tion. After extraction from the skull, brains were further
post-fixed overnight in fresh 4% PFA/PB solution, and
cryoprotected with 30% sucrose in PB. Coronal free-
floating striatal and mesencephalic sections (30-μm thick)
were prepared using a freezing microtome (Leica) and col-
lected in 10 regularly spaced series. For quantitative PCR,
brains were rapidly removed from the skull and striata,
ventral mesencephalon and cortex were dissected on hu-
midified filters at 4°C. Tissues were then frozen in liquid
nitrogen and kept at −80°C until use.
Real-time polymerase chain reaction (PCR)
Real-time quantitative (q)PCR was performed as de-
scribed [15]. The primer sequences were as follows:
mouse Dat forward 5-CGC TGG AGG CAG TCG AA-3,
and reverse 5-CGG AGC ATT TGC TTT TAC TCA TG-
3; mouse Cd11b forward 5-GAT GCT TAC CTG GGT
TAT GCT TCT-3, and reverse 5-CCG AGG TGC TCC
TAA AAC CA-3; mouse Dap12 forward 5-TGG TGT
TGA CTC TGC TGA TTG C-3, and reverse 5-CCT TCC
GCT GTC CCT TGA C-3. Primer sequences of house-
keeping gene were as follow: mouse Hprt forward 5-CTT
CCT CCT CAG ACC GCT TTT-3, and reverse 5-AAC
CTG GTT CAT CAT CGC TAATC-3; mouse Gapdh for-
ward 5-TGT GTC CGT CGT GGA TCT GA-3, and re-
verse 5-CCT GCT TCA CCA CCT TCT TGA-3.
Kinugawa et al. Journal of Neuroinflammation 2013, 10:82 Page 3 of 12
http://www.jneuroinflammation.com/content/10/1/82
Measurement of striatal MPP+ levels
Mice were euthanized 90 minutes after one i.p. injection of
30 mg/kg MPTP-HCl, and their striata were recovered and
treated with 500 μL 0.1 N HClO4 before being processed
for HPLC using UV detection (295-nm wavelength).
Measurement of striatal dopamine, DOPAC and HVA levels
Seven days after the last MPTP injection, mice were eu-
thanized and their striata were dissected out and treated
with 0.1 N perchloric acid containing 0.05% disodium
ethylenediaminetetraacetic acid (EDTA) and 0.05% sodium
metabisulfite. Striatal tissue content in dopamine, 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovanillic
acid (HVA) was assessed by high performance liquid chro-
matography (HPLC) using electrochemical detection with
a potential set at +0.65 V.
Immunohistochemistry
Immunohistochemical staining on mouse brain sections
was performed as previously described [16]. The follow-
ing primary antibodies were used: anti-TH (1:1000; Pel-
Freez Biochemicals), anti-Iba1 (1:500; Wako Chemicals).
Staining was revealed by the ABC method (Vector La-
boratories) with 3,3-diaminobenzidine (DAB) as the per-
oxidase substrate. Mouse sections were counterstained
with thionin solution (Nissl stain).
For double-staining experiments, brain sections were
simultaneously incubated with two primary antibodies:
anti-CD11b (rat - 1:250; Serotec, Oxford, England), anti-
DAP12 (rabbit- 1:100; Chemicon International, Merk
Millipore, Molsheim, France). Sections were then incubated
in specific CY3- or Alexa488-conjugated secondary anti-
bodies (Jackson ImmunoResearch Europe, Suffok, England)
at 1:1000 dilution for 120 minutes at room temperature.
Image and data analysis
DAB-immunostained sections were analyzed by bright-
field microscopy, using a Leitz microscope equipped
with image analysis software (Mercator, ExploraNova, La
Rochelle, France). TH+ and Nissl+ cell bodies were quan-
tified stereologically on regularly spaced sections cover-
ing the whole substantia nigra pars compacta (SNpc)
using the VisioScan stereology tool. The investigator
performing the quantification was blinded to the treat-
ment and genotype groups during the analysis. Fluores-
cent sections were analyzed on a Zeiss Axioplan 2 using
ExploraNova FluoUp 1.0 software. Striatal TH optic
densitometry was measured by image analysis software
(Mercator, ExploraNova).
Statistics
All values are expressed as the mean ± standard error of
the mean (SEM). Differences in means between two
groups were analyzed using the two-tailed Student’s t-
test, or when data were not normally distributed, with
the nonparametric Mann–Whitney U-test. Differences
in means among multiple datasets were analyzed using
one- or two-way analysis of variance (ANOVA) with
time, treatment, or genotype as the independent factors.
When ANOVA showed significant differences, pairwise
comparisons between means were tested by the Tukey
post hoc analysis. When data were not normally distrib-
uted, ANOVA on ranks was used (Kruskal-Wallis test
followed by pairwise comparison using the Dunn test).
In all analyses, P-values of less than 0.05 were consid-
ered significant (SigmaStat Statistical Software, Systat
Software, Inc., San Jose, CA, USA).
Results
Microglial DAP12 contributes to the LPS-induced
dopaminergic neurotoxicity in vitro
The involvement of the microglial DAP12 and CD11b
proteins in the pathological induction of DN death was
first investigated in vitro using mixed cultures of mesen-
cephalic neurons and microglial cells (Figure 1A). In
these cultures, the survival of DA neurons was assessed
by measuring the number of neurons expressing TH, the
rate-limiting enzyme of the dopamine synthesis pathway.
The number of TH-immunoreactive neurons was not
significantly different when mesencephalic neurons were
cultured in the absence or in the presence of non-
stimulated microglia (Figure 1B). This showed that in this
co-culture system, non-stimulated microglia do not in-
duce DN death. By contrast, when mesencephalic neurons
were cultured with WT microglia stimulated by LPS (100
ng/mL), the number of TH-expressing neurons decreased
by 20.6% ± 3.9% (P = 0.0096, Dunn test; Figure 1B).
Addition of LPS alone to DN cultures was not neurotoxic
(98.5% ± 3.7%, P = 0.732, Dunn test; Figure 1B), showing
that the toxic effect of LPS is not cell-autonomous. These
experiments show that, as reported previously [17], LPS-
activated microglia are toxic for DN.
It has been shown that CD11b is involved in LPS-
induced neurotoxicity of microglia [4]. In addition, CD11b
acts in synergy with DAP12 to induce the developmental
neuronal death in the hippocampus [9]. Based on these
data, we investigated the role of DAP12 in LPS-induced
dopaminergic neurotoxicity of microglia. Figure 1B shows
that activation of DAP12-deficient microglia with LPS
caused significantly less DN death as compared to WT
microglia (8.3% ± 1.5%; P = 0.015, Dunn test). These re-
sults show that like CD11b, DAP12 contributes also to the
LPS-induced neurotoxicity of microglia.
Microglial DAP12 and CD11b contribute to the
MPP+-induced dopaminergic neurotoxicity in vitro
We next investigated the role of microglial DAP12 and
CD11b in a more relevant model of PD-associated
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dopaminergic cell death. We thus cultured mesenceph-
alic neurons alone or with WT, DAP12- or CD11b-
deficient microglia and monitored the selective death of
DN induced by the neurotoxin MPP+ [18]. As expected,
MPP+ treatment of mesencephalic neuronal cultures in-
duces, on average, a 20% DN cell loss (Figure 1C). When
mesencephalic neurons were co-cultured with WT
microglia, MPP+ induced stronger loss of TH-expressing
cells than when DN were cultured alone (45.3% ± 2.1%,
P = 0.004, Dunn test) (Figure 1C). Noteworthy, when
mesencephalic neurons were co-cultured with DAP12-
or CD11b-deficient microglia, application of MPP+ induced
significantly less death compared to WT microglial cells
(DAP12KI: 37.8% ± 0.9%, P = 0.035; CD11b−/−: 34.8 ± 1.5%,
P = 0.012, Dunn test). These results show that microglial
DAP12 and CD11b participate in non-cell autonomous
mechanisms of DN cell death induced by MPP+.
In some systems, the mechanism of neuronal death in-
duced by activated microglial cells involves the CD11b-
dependent production of ROS [4,9]. This raises the
Figure 1 Microglial Dap12 and CD11b contribute to lipopolysaccharide (LPS)- and 1-methyl-4-phenylpyridinium (MPP+)-induced
dopaminergic neurotoxicity in vitro. (A) Representative image showing tyrosine hydroxylase (TH)-expressing dopaminergic neurons (red) co-
cultured with CD11b-positive microglial cells (green). Scale bar: 50 μm. (B) Quantification of TH+ neurons in LPS-treated neuronal cultures with or
without microglial cells. In LPS-treated neuronal cultures, addition of wild-type (WT) microglial cells (blue bar) results in significant neurotoxicity as
compared to untreated cultures with or without WT microglia. LPS-induced neurotoxicity is attenuated in the presence of DAP12-deficient
(Dap12 KI) microglia (red bar) compared to WT microglia. Data are expressed as mean ± standard error of the mean (SEM). *P <0.01 compared to
untreated mixed cultures; #P <0.05 compared to LPS-treated mixed cultures with WT microglia. (C) Quantification of TH+ neurons in MPP+-treated
neuronal cultures in the presence or absence of microglial cells from WT (blue bar), Dap12 KI (red bar) or Cd11b KO (green bar) mice. In pure
neuronal cultures, MPP+ induces a 20% TH+ cell loss. *P <0.001 compared to untreated neuronal cultures. Addition of WT microglial cells in MPP
+-treated cultures further increases dopaminergic cell death (45% neuronal loss). In neuron/microglia co-cultures, MPP+-induced neurotoxicity is
attenuated in the presence of either DAP12- or CD11b-deficient microglia compared to WT microglia. #P <0.01 compared to untreated mixed
neuron/microglia and pure neuronal cultures; §P <0.05 compared to MPP+-treated mixed cultures with WT microglia. (D) Quantification of
microglia-derived reactive oxygen species (ROS) level in mixed neuron/microglia cultures under basal condition or 24 h after MPP+ exposure.
Treatment of mixed neuron/microglia cultures with MPP+ results in a rise in microglial-derived ROS whose levels were of similar magnitude
between microglial genotypes. *P <0.01 compared to their respective untreated mixed cultures (Dunn test).
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possibility that in mesencephalic neuronal cultures, the
death of DN induced by MPP+-stimulated microglia is
mediated, at least in part, by the DAP12- and CD11b-
dependent production of ROS. To test this hypothesis,
we first established an assay to measure microglial cell-
derived ROS production. We took advantage of the
property of O2
.- to specifically oxidize dihydroethidium
(DHE) to ethidium, which then binds to the nucleic
acids in the cells in which it has been produced [19]. We
thus measured the production of ROS by WT, DAP12-
deficient and CD11b-deficient microglia co-cultured with
mesencephalic neurons challenged or not with MPP+. As
expected, exposure of neuron/microglia co-cultures with
MPP+ induced a significant increase in the intensity of
ethidium production by microglial cells (17.2% ± 1.3%,
P = 0.006, Dunn test) (Figure 1D). Yet, the same increase
was detected when DAP12- or CD11b-deficient microglia
were co-cultured with WT neurons (DAP12 KI: 15.1% ±
0.9%, P = 0.752; CD11b KO: 15.0% ± 0.7%, P = 0.261 com-
pared to WT microglia; Dunn test). This result shows that
in contradiction with a previous in vitro study [5], the
production of ROS following stimulation of microglia by
MPP+-induced DN injury is not dependent on DAP12 or
CD11b.
Increased DAP12 and CD11b expression in the substantia
nigra parallels DA neurons degeneration upon 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication
Our in vitro data show that DAP12 and CD11b contrib-
ute to the toxicity of microglia stimulated by MPP+-in-
duced dopaminergic injury. These results suggest that
microglial DAP12 and CD11b could be involved in
dopaminergic neurodegeneration in the MPTP mouse
model of PD. We thus investigated the involvement of
DAP12 and CD11b in this pathological process.
We first analyzed by qPCR the time course of Dap12
and Cd11b mRNA expression in the mesesencepalon of
mice acutely intoxicated with MPTP. In agreement with
the time course of DA neuron injury previously de-
scribed, we found that dopamine transporter (Dat)
mRNA level was consistently decreasing from day 1 on-
ward (Figure 2A). In contrast, Cd11bmRNA levels sig-
nificantly increased from the first day after intoxication
(Figure 2A). Similarly, analysis of Dap12 mRNA level
Figure 2 Microglial expression of Dap12 is induced in the mouse ventral mesencephalon following 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) intoxication. (A) Real-time quantitative PCR analysis of Dat, Cd11b and Dap12 transcripts in the ventral
mesencephalon before (NaCl) and after MPTP intoxication at the indicated times. *P <0.05 compared to NaCl-treated controls; Holm-Sidak post
hoc analysis. RQV, relative quantity value; d, days. (B) Double immunofluorescent staining for CD11b (red) and DAP12 (green) on mesencephalic
tissue sections from control or MPTP-injected mice 2 days after toxin exposure. The arrows indicate hypertrophied and double-labeled microglial
cells at the level of the SN pars compacta. Scale bar: 30 μm.
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revealed a marked three-fold increase one day after MPTP
intoxication (Figure 2A). This observation suggests that
microglial cell activation following MPTP intoxication
may trigger increased DAP12 and CD11b expression in
the injured SN. To examine such possibility, we analyzed
the cellular expression of DAP12 and CD11b in the SN of
control and MPTP-intoxicated mouse by immunostaining.
In saline-injected control mice, CD11b-immunoreactive
microglial cells were found throughout the SN. These cells
displayed a small cell body and ramifications, which are
reminiscent of non-activated microglia. In these cells,
DAP12 expression was barely detectable (Figure 2B). In
MPTP-injected mice, CD11b staining markedly increased
in numerous nigral microglial cells of the SN. In some,
but not all microglia, a strong DAP12-immunoreactivity
could also be detected (Figure 2B). These DAP12-
expressing microglia displayed a large cell body and an
ameboid-like shape characteristic of a pathological acti-
vation state.
MPTP-induced dopaminergic neuron injury is not
attenuated by DAP12 or CD11b deficiency
Our results establish that microglial DAP12 and CD11b
contribute to the death of DA neurons in vitro upon
MPP+ exposure. They further show that both DAP12
and CD11b are expressed by microglial cells in the SN
when DN are prone to degenerate upon MPTP intoxica-
tion. DAP12 and CD11b were also reported to be neces-
sary to induce neuronal death during development. It is
therefore tempting to speculate that in the MPTP mouse
model of PD, DAP12 and CD11b are involved in the
death of DN as well. This hypothesis is further sup-
ported by the fact that in a similar model of DN degen-
eration induced by subchronic injection of MPTP, the
death of DN was found to be attenuated in CD11b-
deficient mice [5].
Before analyzing the involvement of DAP12 in MPTP-
induced neurotoxicity, we checked the integrity of the
nigrostriatal pathway in DAP12 mutant mice. We assessed
the extent of nigrostriatal pathway injury by quantifying
the number of TH-positive neurons in the SN and the
level of striatal TH-immunoreactivity as an index of dopa-
minergic terminal integrity. No significant differences
were found in the number of TH-positive neurons and in
striatal TH-immunoreactivity between saline-injected
DAP12+/+ and DAP12KI animals (Figure 3A and B). Like-
wise, the number and morphology of Iba1+-microglial
cells in the SN were similar between DAP12+/+ and
DAP12KI mice (Figure 3C). These results indicate that the
development and maintenance of the dopaminergic
nigrostriatal pathway is not compromised by DAP12 defi-
ciency. Then, a subchronic regimen of MPTP intoxication
was given to DAP12KI and CD11b−/− mice and their WT
littermates. Mice were sacrificed 21 days after the last
injection. In control DAP12+/+ mice, we found that MPTP
injection induced a significant death of TH-positive neu-
rons as well as the loss of striatal TH+-dopaminergic fibers
when compared to saline-injected animals (Figure 4A).
Surprisingly however, alteration of TH-positive neurons
and TH-positive fibers induced by MPTP injection in the
DAP12KI or in the CD11b−/− mutant mice, was the same
as those observed in their WT littermates (Figure 4A and
B). These results show that DAP12 and CD11b are not in-
volved in the death of DN in the MPTP mouse model of
PD using a subchronic mode of intoxication.
These results seem in contradiction with our in vitro
data and to a previous study showing that CD11b defi-
ciency attenuates the DN death upon sub-chronic in-
toxication of mice by MPTP. Whether such discrepancy
may be related to the mode of dopaminergic injury and
intensity of microglial cell activation and neuroin-
flammation was then tested by applying an acute regi-
men of MPTP intoxication. In this acute MPTP mouse
model, non-cell autonomous mechanisms of neuro-
degeneration orchestrated by activated microglial cells
are known to be involved in the demise of DA neurons
[1]. In these conditions, we found that neither DAP12-
nor CD11b-deficiency attenuates the loss of DN in the
SN or the density of DA fibers in the striatum following
MPTP exposure of mice (Figure 4C and D). This was
further confirmed by similar decrease in striatal content
of dopamine and its metabolites DOPAC and HVA
between MPTP-intoxicated DAP12KI and WT mice
(Table 1). Importantly, striatal MPP+ levels were of
the same magnitude between MPTP-intoxicated
DAP12KI and WT mice ruling out the possibility that
an increase in MPTP metabolism could have masked
a putative neuroprotection in DAP12KI animals (Table 2).
(See figure on previous page.)
Figure 3 The nigrostriatal pathway and microglial substantia nigra (SN) content are unaltered in DAP12-deficient mice. (A) Representative
photomicrographs of striatal sections immunostained for tyrosine hydroxylase (TH) from wild-type (WT) and DAP12KI mice. Right panel: quantification
of striatal TH immunoreactivity (optical density). Bars represent the mean optical density. Scale bar: 100 μm. (B) Representative photomicrographs of
mesencephalic sections immunostained for TH from WT and DAP12KI mice. Right panel: quantification of TH+ dopaminergic neurons in the SN pars
compacta. Bars represent the mean number of total nigral TH+ neurons. Scale bar: 300 μm. (C) Representative photomicrographs of mesencephalic
sections from WT and DAP12KI mice and immunostained for the microglial marker Iba1. Dashed boxes delineate the area for higher magnification
views shown on the right. Scale bar: left, 400 μm; right, 50 μm. Right panel: quantification of Iba1+ microglial cells in the SN pars compacta of WT and
DAP12KI mice. Bars represent the mean number of Iba1+ microglial cells in the SN pars compacta.
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Taken together, these results show that microglial DAP12
or CD11b deficiencies are able to induce DN neuro-
protection in vitro, but not in vivo in two different MPTP
mouse models of PD.
Discussion
Mounting evidence supports the view that innate immun-
ity orchestrated by microglial cells, the tissue macrophages
of the CNS, may contribute to neurodegeneration in PD
Figure 4 Mouse deficiency in either DAP12 or CD11b does not mitigate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
nigrostriatal pathway injury in vivo. Quantification of striatal tyrosine hydroxylase (TH) immunoreactivity (optical density) and TH+ dopaminergic
neurons in the SN pars compacta from DAP12KI or CD11b KO and their wild-type (WT) littermates at day 21 (A and B; subchronic regimen of
intoxication) or 7 (C and D; acute regimen of intoxication) after the last injection of MPTP (black bars) or saline solution (white bars). Irrespective
of the mode of intoxication (subchronic or acute), a significant loss of both striatal dopaminergic fibers and nigral DN were observed in all
MPTP-treated groups compared to their respective saline controls. No significant differences were found between genotypes. *P <0.001
compared to saline-treated mice, Holm-Sidak post hoc analysis.
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[1,20]. The microglial response to DN injury sets off dele-
terious mechanisms among which, induction of catalytic
systems that brings about the production of toxic amounts
of oxygen-derived and nitrogen-derived species, is thought
to play a critical role [1]. This process, known as the oxi-
dative burst, is generally used by phagocytic cells to elim-
inate invading pathogens. This process has also been
described in the CNS when microglial cells trigger the de-
velopmental death of supernumerary neurons through the
production of superoxide ions [9,11,21,22]. The signaling
molecules involved in such a developmental process have
shown remarkable similarities with those implicated in the
elimination of pathogenic cells by peripheral innate im-
mune cells. Thus, developmental neuronal death in the
hippocampus requires the microglial CD11b integrin and
DAP12 adaptor protein, which cooperate to promote the
production of toxic amounts of superoxide ions (9). Inter-
estingly, prior studies using both in vitro and in vivo ex-
perimental models recapitulating microglial-associated
non-cell autonomous mechanisms of dopaminergic cell
death, demonstrated that microglial CD11b is likely to
play a central role in the demise of DA neurons as well
[5]. These data raise the tantalizing hypothesis that devel-
opmental mechanisms of microglial-induced neuronal cell
death could be reactivated during adulthood in a PD-
associated pathological context. In support of this hy-
pothesis, we found that DAP12 expression is strongly
stimulated in microglial cells following MPTP-induced
nigrostriatal pathway injury whereas it is barely detectable
in the SN of saline-injected mice. This lack of DAP12 ex-
pression in the normal adult SN is in accordance with
previous studies showing that whereas DAP12 could be
detected in the hippocampus of E17 mouse embryos, it
was not further observed in the brain of 17 day-old mice
[11]. Yet, other studies were able to show DAP12 expres-
sion mostly in microglial cells and rare neurons in human
and mouse cerebral cortex suggesting that under physio-
logical conditions, DAP12 expression may differ from one
brain region to another [23]. It is interesting to note that
after MPTP intoxication, DAP12 was exclusively detected
in hypertrophied and strongly CD11b-labeled microglial
cells reminiscent of activated cells. Yet, not all activated
CD11b-positive microglial cells expressed DAP12, sug-
gesting that pathological induction of this adaptor signal-
ing molecule is restricted to specific cells with particular
functions such as elimination of neurons committed to
die [9,11]. In line with a link between DAP12 upregulation
and microglial cell activation, the time course of both pro-
cesses was similar raising the possibility that as previously
shown for CD11b [5], DAP12 may represent another im-
portant effector function of activated microglial cells dur-
ing DA neurodegeneration.
We have now shown that microglial DAP12- or
CD11b-deficiency is associated with increased DN sur-
vival in a mouse in vitro model of PD recapitulating
microglial-associated non-cell autonomous mechanisms
of neuronal cell death. These results confirmed those
reported by Hu et al. (2008), but also provide further
evidence that microglial CD11b and DAP12 may act in
concert to induce neurotoxicity as in the developing
hippocampus [5,9]. Yet, in contrast to previous studies
[3,5], deficiency of microglial CD11b or DAP12 did not
change the level of superoxide ions produced by acti-
vated microglial cells in vitro. Such a difference might be
explained by the fact that we directly measured the
intracellular microglial superoxide ions whereas in the
other studies total extracellular ROS was measured [3,5].
DAP12- and CD11b-deficiency lead to partial neuro-
protection of MPP+-exposed mesencephalic neurons
cultured with microglia. In addition, DAP12 and CD11b
were upregulated in nigral microglial cells following
MPTP-induced nigrostriatal pathway injury. This prompted
us to test the possibility that a microglial CD11b/DAP12
pathway could be involved in non-cell autonomous mecha-
nisms of DN cell death in the MPTP mouse model of PD.
Surprisingly, neither DAP12- nor CD11b-deficiency in the
mouse were associated with neuroprotection in this
experimental model of PD. However, studying the same
CD11b−/− transgenic line with the same genetic back-
ground, gender and age, it has been found that CD11b-
deficient mice were strongly protected against MPTP
toxicity [5]. Such divergent results might not be due to the
use of different doses of MPTP. Indeed, we used both acute
and subchronic regimens of MPTP exposure, correspond-
ing to a cumulative dose of 80 mg/kg and 150 mg/kg of
Table 1 Striatal monoamine levels (pM/mg tissue)
Dopamine DOPAC HVA
Saline
DAP12+/+(n = 5) 86.1 ± 5.2 13.8 ± 1.7 8.9 ± 1.5
DAP12KI (n = 3) 81.9 ± 10.7 14.6 ± 2.2 9.4 ± 1.1
MPTP
DAP12+/+(n = 5) 5.6 ± 0.9 4.8 ± 0.8 5.2 ± 0.6
DAP12KI (n = 3) 6.5 ± 1.3 4.1 ± 0.5 4.9 ± 0.9
Striatal dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic
acid (HVA) levels in DAP12+/+and DAP12KI mice at 7 days after the last MPTP
injection do not differ (P >0.05; Mann–Whitney U-test) between groups. Data
represent means ± SEM for the indicated number of mice.
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Table 2 Striatal 1-methyl-4-phenylpyridinium (MPP+)
levels
MPP+ (ng/mg tissue)
DAP12+/+ 6.11 ± 2.08
DAP12KI 5.86 ± 2.43
Striatal MPP+ levels in DAP12+/+ and DAP12KI mice at 90 minutes after a single
MPTP injection did not differ (P = 0.91; Mann–Whitney U-test) between
groups. Data represent means ± SEM for five mice per group.
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MPTP-HCl, respectively, whereas Hu and collaborators
used a cumulative dose of 90 mg/kg. Alternatively, the
route of MPTP administration (i.p. versus subcutaneous)
could underline different outcomes and will need further
investigation. In spite of the uncertainty about the critical
role of CD11b in microglial-associated DA cell death
in vivo, an original finding of our study is that the DAP12 is
not crucially involved in the demise of DN in the MPTP
mouse model of PD. Therefore, while the developmental
CD11b/DAP12 pathway is likely to be reactivated in a PD-
like neuropathological context, it is unlikely to play a pri-
mary role in neurodegeneration in vivo.
It is currently unknown why microglial CD11b or
DAP12 deficiency is protective in vitro but not in vivo.
Yet, one may expect that cellular interactions and signal-
ing are much more complex in an integrated biological
system than in culture. Hence, inhibition of the CD11b/
DAP12 pathway in vivo could be compensated by
alternative mechanisms, such as activation of Toll-like
receptor-4 (TLR4), which is exclusively expressed by
microglial cells in the CNS [24]. Previous findings have
underlined the role for TLR4 in ‘sterile inflammation’ in-
duced by neuronal damage [25]. Interestingly, among
the TLR4 ligands potentially released by dying/suffering
neurons during CNS injury, the heat shock protein 60
(Hsp60) which has been implicated in microglia-induced
neurotoxicity, is believed to function as an endogenous
danger signal to the immune system indicating tissue
injury [26]. Since Hsp60 has also been described as an
agonist of the DAP12-associated receptor TREM2 [27],
one may not exclude the possibility that defective
Hsp60/TREM2/DAP12 signaling achieved in DAP12-
deficient mice may be substituted by activation of the
Hsp60/TLR4 pathway to mediate microglial activation
and neurotoxicity in vivo. Since activation of the
TREM2/DAP12 pathway has been shown to inhibit TLR
responses in macrophages [28,29], DAP12 deficiency in
MPTP-intoxicated mice could amplify the pathological
value of the Hsp60/TLR4 signaling even more, thus
masking the putative benefit of DAP12 ablation. Al-
though our in vitro data do not support this latter
scenario, this will need to be tested in vivo in WT and
DAP12-deficient mice challenged by LPS infusion into
the SN.
Conclusions
In summary, we have shown that microglial DAP12 and
CD11b contribute partially to microglia-associated DN
cell death in vitro and that DAP12 is reactivated during
PD-like nigrostriatal pathway injury induced by MPTP
intoxication in adult mice. Yet, genetic ablation of either
DAP12 or CD11b in mice does not improve MPTP-
associated neuropathological alterations suggesting that
this developmental microglia-induced neuronal death
mechanism is unlikely to play a significant role in the
pathophysiology of PD and should not, therefore, be con-
sidered further as a promising therapeutic target for this
neurodegenerative disorder.
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